Roivant Sciences Ltd.
ROIV
Jodie situation report
Roivant Sciences Ltd.'s current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 37 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 17 directly disclosed connections are confirming.
- ROIV's market-adjusted activity becomes unusual and at least one connected name confirms.
Invalidation: The isolated read changes if ROIV's group or a disclosed connection begins moving with it.
Who this business touches
The relationships behind ROIV
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
ALNYAlnylam Pharmaceuticals, Inc.supplierMay 29, 2025 ▾
“LNP platform : • Technology used in the first systemic RNA-LNP product to receive FDA-approval, Alnylam’s Onpattro (patisiran) for the treatment of polyneuropathy caused by hereditary ATTR amyloidosis.”
PFEPfizer, Inc.supplierMay 29, 2025 ▾
“In exchange for Pfizer’s inventory of these compounds, Priovant paid Pfizer $10.0 million.”
Depended on by
IMVTImmunovant, Inc.partnerMay 20, 2026 ▾
“108 Table of Contents Unallocated costs include: • personnel-related expenses, such as salaries, stock-based compensation and benefits, for research and development personnel; • costs allocated to us under our services agreements with Roivant Sciences Ltd.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 16 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
ROIV is currently a Follower in the organic co-movement group Biotechnology. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.